Insights

Value, Affordability, and…
Health Policy and Regulation

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Health Technology Assessment…
Cancer

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

$Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover$

Health Technology Assessment…
Measuring and Valuing Outcomes
Cancer

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

EQ-5D and PROMs
Measuring and Valuing Outcomes
Clinical Outcomes

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Health Technology Assessment…
Value, Affordability, and…

News and Insights

Latest Research & Publications

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Uncertainty and Risk in HTA Decision Making

The Distribution of the EQ-5D-5L Index in Patient Populations

Improving Efficiency and Resource Allocation in Future Cancer Care

Four Case Studies to Explore the Added Value of Oxford AHSN

All Publications

Filter results by

Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool

R&D For New Drugs To Tackle AMR Is A High Return Investment For All EU Member States

Filter results by

Newsroom

Subscribe To Our Newsletter

Share on Mastodon